Evidence map›Paper›PMID 33987116›Full record

ArticleEuropean journal of case reports in internal medicine2021

Reversible Neurological Adverse Reaction to Apixaban.

Eduardo Rodrigues Cernadas, Catarina Dionisio, Dália Estevão, Leopoldina Vicente

Abstract read
In one paragraph

Article in European journal of case reports in internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eduardo Rodrigues CernadasCentro Hospitalar Universitário Cova da Beira, Covilhã, Portugal.
Catarina DionisioCentro Hospitalar Universitário Cova da Beira, Covilhã, Portugal.
Dália EstevãoCentro Hospitalar Universitário Cova da Beira, Covilhã, Portugal.
Leopoldina VicenteCentro Hospitalar Universitário Cova da Beira, Covilhã, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins for deep vein thrombosis prophylaxis. The authors report the case of an 80-year-old woman followed by her cardiologist for permanent atrial fibrillation who was prescribed apixaban. Within a few days the patient developed neurological symptoms of imbalance and non-vertiginous dizziness, headache, confusion/disorientation and asthenia. Her symptoms began to resolve after the drug was stopped, with return to baseline function within 72 h. The plasma concentration of apixaban was 4 times higher than the laboratory upper limit of normal. Symptoms did not recur when the patient was switched to rivaroxaban therapy. LEARNING POINTS: Prescribing of the novel oral anticoagulant factor Xa inhibitors is increasing.Reversible neurological effects may occur in some patients, for instance in those with advanced age or chronic renal failure.

Indexed as

adverse drug reactionApixabanneurological symptoms

Identifiers

PMID33987116
PMCPMC8112088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.